Marshwinds Advisory’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Marshwinds Advisory’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-10,000	Closed	-$16K	–	148
2015 Q2	$16K	Hold	10,000	–	–	0.01%	140
2015 Q1	$21K	Hold	10,000	–	–	0.01%	145
2014 Q4	$24K	Hold	10,000	–	–	0.01%	148
2014 Q3	$28K	Hold	10,000	–	–	0.01%	142
2014 Q2	$34K	Buy	+10,000	New	+$581K	0.02%	144

Other funds holding OREX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshwinds Advisory's OREX Position: Q3 2015 in Review

Marshwinds Advisory sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2015, closing a stake of 10,000 shares — an estimated $16K sold.

Marshwinds Advisory first reported a position in OREX in Q2 2014 and held it in 5 quarters. The position peaked at $34K in Q2 2014. 132 funds tracked by Wall St. Rank hold OREX as of Q3 2015.

Marshwinds Advisory reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
Marshwinds Advisory sold 10,000 Orexigen Therapeutics, Inc. shares in Q3 2015, an estimated $16K.
Marshwinds Advisory first reported a position in Orexigen Therapeutics, Inc. in Q2 2014 and held it in 5 quarters.
Marshwinds Advisory's Orexigen Therapeutics, Inc. position peaked at $34K in Q2 2014.
132 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2015.

Based on Marshwinds Advisory's 13F filing for Q3 2015, filed 7 Oct 2015.